1-环戊基-6-(3-乙氧基-4-吡啶基)-3-乙基-4,5-二氢-1H-吡唑并[3,4-d]嘧啶-4-酮 | 158020-82-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 1-环戊基-6-(3-乙氧基-4-吡啶基)-3-乙基-4,5-二氢-1H-吡唑并[3,4-d]嘧啶-4-酮
• 英文名称: 1-cyclopentyl-6-(3-ethoxypyridin-4-yl)-3-ethyl-5H-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one
• CAS: 158020-82-7
• 化学式: C₁₉H₂₃N₅O₂
• 分子量: 353.4
• InChiKey: MFKZGAAAKCDLHM-UHFFFAOYSA-N

物化性质

• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  81.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
  申请人：Indiana University Research and Technology Corporation

  公开号：US10456404B2

  公开（公告）日：2019-10-29

  Described herein is the identification of cGMP-specific phosphodiesterase upregulation in cystic kidney diseases. Also described is the use of cGMP-specific phosphodiesterase inhibitors for preventing the progression and/or treatment of cystic kidney diseases. Other aspects described provide medicaments for preventing the progression and/or treating cystic kidney diseases, and methods of diagnosing cystic kidney disease.

  本文描述了囊性肾病中 cGMP 特异性磷酸二酯酶上调的鉴定。还描述了使用 cGMP 特异性磷酸二酯酶抑制剂预防和/或治疗囊性肾病的方法。所描述的其他方面提供了用于预防囊性肾脏疾病进展和/或治疗的药物，以及诊断囊性肾脏疾病的方法。
• Novel use of selective pde5 inhibitors
  申请人：Ghofrani Ardeschir

  公开号：US20050107394A1

  公开（公告）日：2005-05-19

  The invention relates to the novel use of PDE5 inhibitors for the treatment of patients in which a mismatch is present.

  本发明涉及将 PDE5 抑制剂用于治疗存在错配的患者的新方法。
• Composition comprising a pde4 inhibitor and a pde5 inhibitor
  申请人：Dunkern Torsten

  公开号：US20060094723A1

  公开（公告）日：2006-05-04

  The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.

  本发明涉及联合使用 PDE4 抑制剂和 PDE5 抑制剂治疗磷酸二酯酶 4（PDE4）和/或磷酸二酯酶 5（PDE5）有害的疾病。
• Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
  申请人：Wollin Stefan-Lutz

  公开号：US20060148693A1

  公开（公告）日：2006-07-06

  The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental.

  本发明涉及肺表面活性物质和PDE5抑制剂的联合用药，用于治疗肺表面活性物质功能障碍和/或磷酸二酯酶5（PDE5）活性有害的疾病。
• USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE
  申请人：ALTANA Pharma AG

  公开号：EP1461022A2

  公开（公告）日：2004-09-29